Abstract:Background Fibroblast growth factor receptor 2 (FGFR2) alteration, including gene amplification and fusion, are closely associated with poor prognosis and low response to chemotherapy and immunotherapy in advanced gastric cancer (GC) patients. The acquired alternative activation of bypass signaling is an important cause of FGFR2 inhibitor insensitivity and resistance. Src homology region 2-containing protein tyrosine phosphatase 2 (SHP2) is the shared downstream of all Receptor tyrosine kinases (RTKs). Meanwhile, SHP2 is also an important downstream molecule of Programmed cell death protein-1 (PD-1) signaling. Herein, blocking SHP2 and FGFR2 may be able to suppress tumor progression with both targeted intervention and immune activation in gastric cancers with FGFR2 alteration. Methods Cell Counting Kit-8 and Annexin V-FITC Apoptosis Detection Kit were used to evaluate cell proliferation and apoptosis. Western blot was used to detect the expression levels of proteins in several FGFR2-initiated downstream signaling cascades. Primary human T cells were separated from human peripheral blood. PD-1 and IFN-γ expressions of T cells were detected by flow cytometry. Finally, drug-stimulated T cells were incubated with SNU16 cells for tumor-killing capacity assessment by CFSE-PI double staining. Results We found that the combination administration of SHP099 and AZD4547 significantly inhibited cancer cell proliferation in vitro in FGFR2i-resistant model derived from ascites of a female GC patient with FGFR2 amplification, two FGFR2-amplified GC cell lines and GC cells transfected with one kind of FGFR2 fusion. We detected a more remarkable suppression of the downstream signals of FGFR2 in combined therapy, implying that SHP099 may be able to overcome FGFR2 inhibitor resistance by suppressing RAS/ERK and PI3K/AKT pathways. Given the immunosuppressive role of SHP2 under PD-1 signaling induction, we also proved that SHP099 treatment can significantly increase the secretion level of IFN-γ and downregulated the expression of PD-1 in human CD8+ T cells. T cells activated by SHP099 had a more potent anti-tumor ability to FGFR2-amplified gastric cell line. Conclusions In general, SHP099 can not only boost the tumor-cytotoxicity effect and overcome the drug resistance of AZD4547, but also activate cytotoxic T lymphocytes to kill tumor cells in FGFR2-alterated gastric cancers. Our results demonstrate the utility and feasibility of combining SHP2 to FGFR2 inhibitors for GC patients with FGFR2 alteration.

Predictive Biomarkers and Personalized Medicine FGFR 2 Gene Ampli fi cation in Gastric Cancer Predicts Sensitivity to the Selective FGFR Inhibitor AZD 4547

Fgfr2 Gene Amplification in Gastric Cancer Predicts Sensitivity to the Selective Fgfr Inhibitor Azd4547

Multiple Receptor Tyrosine Kinase Activation Attenuates Therapeutic Efficacy of the Fibroblast Growth Factor Receptor 2 Inhibitor AZD4547 in FGFR2 Amplified Gastric Cancer.

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer

Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

576 Blocking FGFR2 and SHP2 Can Effectively Suppress Tumor Progression in Gastric Cancers with FGFR2 Alteration

Prognostic impact of fibroblast growth factor receptor 2 gene amplification in patients receiving fluoropyrimidine and platinum chemotherapy for metastatic and locally advanced unresectable gastric cancers

FGF19 Genetic Amplification As a Potential Therapeutic Target in Lung Squamous Cell Carcinomas.

FGFR2 Alteration As a Potential Therapeutic Target in Poorly Cohesive Gastric Carcinoma

FGF18–FGFR2 signaling triggers the activation of c-Jun–YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential

Whole-exome sequencing of alpha-fetoprotein producing gastric carcinoma reveals genomic profile and therapeutic targets

1527P Efficacy and Safety of Infigratinib in Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Patients with FGFR2 Gene Amplification

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.

Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer

HER2, MET and FGFR2 Oncogenic Driver Alterations Define Distinct Molecular Segments for Targeted Therapies in Gastric Carcinoma.

Design, synthesis and biological evaluation of a series of novel pyrrolo[2, 3-d] pyrimidin/pyrazolo[3, 4-d] pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer

FGFR2-fusions define a clinically actionable molecular subset of pancreatic cancer

Comprehensive analysis of the prognostic value and immune infiltration of FGFR family members in gastric cancer

A novel small molecule RK-019 inhibits FGFR2-amplification gastric cancer cell proliferation and induces apoptosis in vitro and in vivo

Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments